首页> 美国卫生研究院文献>Molecular Therapy. Nucleic Acids >Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina
【2h】

Inclusion of the Woodchuck Hepatitis Virus Posttranscriptional Regulatory Element Enhances AAV2-Driven Transduction of Mouse and Human Retina

机译:土拨鼠肝炎病毒转录后调控元件的包含增强AAV2驱动的小鼠和人类视网膜的转导。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) has been included in the transgene cassette of adeno-associated virus (AAV) in several gene therapy clinical trials, including those for inherited retinal diseases. However, the extent to which WPRE increases transgene expression in the retina is still unclear. To address this question, AAV2 vectors containing a reporter gene with and without WPRE were initially compared in vitro and subsequently in vivo by subretinal delivery in mice. In both instances, the presence of WPRE led to significantly higher levels of transgene expression as measured by fundus fluorescence, western blot, and immunohistochemistry. The two vectors were further compared in human retinal explants derived from patients undergoing clinically indicated retinectomy, where again the presence of WPRE resulted in an enhancement of reporter gene expression. Finally, an analogous approach using a transgene currently employed in a clinical trial for choroideremia delivered similar results both in vitro and in vivo, confirming that the WPRE effect is transgene independent. Our data fully support the inclusion of WPRE in ongoing and future AAV retinal gene therapy trials, where it may allow a therapeutic effect to be achieved at an overall lower dose of vector.
机译:土拨鼠肝炎病毒转录后调控元件(WPRE)已被包括在多项基因治疗临床试验的腺相关病毒(AAV)的转基因盒中,包括那些针对遗传性视网膜疾病的试验。但是,WPRE增加视网膜中转基因表达的程度仍不清楚。为了解决这个问题,首先在小鼠中体外和随后通过视网膜下递送在体内比较了含有带有和不带有WPRE的报告基因的AAV2载体。在两种情况下,通过眼底荧光,蛋白质印迹和免疫组织化学测定,WPRE的存在均导致转基因表达水平显着提高。两种载体在接受临床指示视网膜切除术的患者的人类视网膜外植体中进行了进一步比较,其中WPRE的存在再次导致报告基因表达的增强。最后,使用目前在脉络膜增生症临床试验中使用的转基因的类似方法在体外和体内均获得了相似的结果,证实了WPRE的作用与转基因无关。我们的数据完全支持将WPRE包括在正在进行的和将来的AAV视网膜基因治疗试验中,在该试验中,可以使载体总体剂量较低,从而达到治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号